Dorothea Wessiepe

Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia

Max S. Topp, Nicola Gökbuget, Gerhard Zugmaier et al. · Journal of Clinical Oncology · 2014 · 659 citations

Medicine, Hematology, Oncology +15

A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors

Maxim Kebenko, Marie-Elisabeth Goebeler, M. Wolf et al. · OncoImmunology · 2018 · 176 citations · Full text

Medicine, Oncology, Pharmacology +17

Randomized controlled trials define shape of dose response for Pollinex Quattro Birch allergoid immunotherapy

Margitta Worm, T. W. Higenbottam, Oliver Pfaar et al. · Allergy · 2018 · 36 citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +16

Strong dose response after immunotherapy with PQ grass using conjunctival provocation testing

Stefan Zielen, Piotr Kuna, Werner Aberer et al. · World Allergy Organization Journal · 2019 · 21 citations · Full text

Life Sciences, Immunology, Pharmacology +12

Validation of a menstrual pictogram and a daily bleeding diary for assessment of uterine fibroid treatment efficacy in clinical studies

Claudia Haberland, Anna Filonenko, Christian Seitz et al. · Journal of Patient-Reported Outcomes · 2020 · 10 citations · Full text

Medicine, Gynecology, General Gynecology +13